These findings not only represent a significant step forward in the understanding of IGH::DUX4‐driven leukaemogenesis, but also open a new direction in future drug targeted therapy against the cofactor of oncogenic driver in ALL. The gene discussed is DUX4; the disease is acute lymphoblastic leukemia.